← Leaderboards
Jing Yang
University Of Tx Md Anderson Can Ctr
$4,499,082
Attributed
$4,499,082
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $740.4K · FY2009–20$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,499,082 · 4
By mechanism
R01$3,665,145 · 2
R00$700,147 · 1
K99$133,790 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Steven Grant$1,384,176
- Juan Fueyo$8,546,462
- Min Gyu Lee$8,063,863
- James C Yao$2,907,879
- Xiangsheng Zuo$1,979,525
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTumorMultiple MyelomaCoculture TechniquesIn VitroAntibodiesSignal PathwayBaseNovel StrategiesBone MarrowGrowthAdipocyte DifferentiationBeta CateninApoptosisMalignant NeoplasmsPlasma CellsCaringAdipocytesMediatingDepositionPublic Health RelevanceImmuneRecurrent DiseaseNovel Therapeutics
Grant awards (16)
Role of integrin VLA-6 in suppression of bone formation in myeloma$373,651
R01 · FY2020 · CA · contact PI
Role of integrin VLA-6 in suppression of bone formation in myeloma$353,752
R01 · FY2019 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$307,454
R01 · FY2019 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$48,701
R01 · FY2019 · CA · contact PI
Role of integrin VLA-6 in suppression of bone formation in myeloma$367,446
R01 · FY2018 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$364,696
R01 · FY2018 · CA · contact PI
Role of integrin VLA-6 in suppression of bone formation in myeloma$370,179
R01 · FY2017 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$368,739
R01 · FY2017 · CA · contact PI
Role of integrin VLA-6 in suppression of bone formation in myeloma$370,179
R01 · FY2016 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$370,174
R01 · FY2016 · CA · contact PI
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma$370,174
R01 · FY2015 · CA · contact PI
Anti-beta2 microglobulin as a novel therapeutic agent in multiple myeloma$220,491
R00 · FY2013 · CA · contact PI
Anti-beta2 microglobulin as a novel therapeutic agent in multiple myeloma$238,125
R00 · FY2012 · CA · contact PI
Anti-beta2 microglobulin as a novel therapeutic agent in multiple myeloma$241,531
R00 · FY2011 · CA · contact PI
Anti-beta2 microglobulin mAbs as a novel therapeutic agent in multiple myeloma$49,550
K99 · FY2010 · CA · contact PI
Anti-beta2 microglobulin mAbs as a novel therapeutic agent in multiple myeloma$84,240
K99 · FY2009 · CA · contact PI